REFERENCES
- Worth LJ, Blyth CC, Booth DL, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J. 2008; 38:521–537.
- Parish JM, Blair JE. Coccidioidomycosis. Mayo Clin Proc. 2008; 83: 343–349
- Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005; 41:1217–1223
- Rodenbiker HT, Ganley JP, Galgiani JN, Axline SG. Prevalence of chorioretinal scars associated with coccidioidomycosis. Arch Ophthalmol. 1981; 99:71–75
- Garner A, Klintworth GK. Pathobiology of Ocular Disease: A Dynamic Approach, Vol. 1. New York, USA: Informa Healthcare; 1994: 311–312.
- Hwang JM, Pian D. Iritis presumed as secondary to disseminated coccidioidomycosis. Optometry. 2006; 77:547–553
- Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis. 2000; 30:658–661
- Dewsnup DH, Galgiana JN, Graybill R, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;24:305–310
- Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole, therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med. 1993;119:28–35
- Silling G. Fluconazole: optimized antifungal therapy based on pharmacokinetics. Mycoses. 2002; 45:39–41